Led by Diligent Capital Partners with Plio Limited, Altara Capital, and Tonik management

SINGAPORE and MANILA, Philippines, Dec. 4, 2025 /PRNewswire/ — Tonik Financial, controlling shareholder of Tonik Digital Bank, the Philippines’ first licensed digital-only bank, has raised US$12 million in Pre-Series C financing led by Diligent Capital Partners, with participation from Plio Limited, existing shareholder Altara Capital, and Tonik management. The funding strengthens the regulatory capital position of Tonik Digital Bank under Bangko Sentral ng Pilipinas requirements and supports continued investment in Tonik’s technology platform to accelerate customer acquisition, cross-sell, and automation.

Tonik enters the round with three years of profitability-driven scale, having grown its loan portfolio 15× to US$83 million, while annualized revenue has reached over US$40 million. The bank continues to deliver 25%+ risk-adjusted return on capital (RAROC), and its risk-adjusted gross margin expanded 4.5× over the past twelve months. Contribution margin turned positive  in late 2024, supported by Tonik’s AI-powered credit scoring, disciplined collections, and automation across origination and servicing. With efficiency gains compounding and burn continuing to decline, Tonik’s current trajectory points to cash-flow breakeven around the first half of 2026.

Tonik’s technology and distribution flywheel has become one of the most defensible moats in Southeast Asian consumer finance. The bank integrates regulated, low-cost deposit funding with a deeply seasoned AI risk engine trained on more than three years of proprietary data, and a B2B2C distribution network spanning nearly 400 employers and over 500 retail partners. Its cloud-native stack powers real-time underwriting, behavioral scoring, and automated servicing — lowering cost-to-serve and stabilizing cost of risk — enabling Tonik to scale responsible credit access in a $100B+ latent market where unsecured consumer lending remains the lowest-penetrated in Southeast Asia.

“This round is about scaling with discipline — protecting our capital ratios while growing a profitable, credit-led model,” said Greg Krasnov, Founder & CEO of Tonik. “Tonik was built to prove that financial inclusion in emerging markets can be delivered with truly world-class returns. The momentum we’re seeing in risk performance, technology leverage, and channel scale shows that the model works — and is ready for another 10x in the next 2-3 years.”

“While our fund’s primary focus is on Ukraine and the Black Sea basin, we also back mission-driven Ukrainian founders building globally,” said Dan Pasko, Partner at Diligent Capital Partners. “Our team supported Greg more than a decade ago in one of his prior builds, and many other high-performing Ukrainian leaders are now helping drive Tonik. That continuity gives us deep confidence in execution. Tonik’s unit-economics rigor and technology stack position it to become one of Southeast Asia’s most valuable digital banks over time.”

About Tonik

Tonik is the first digital-only neobank in the Philippines, operating under a full banking license from the Bangko Sentral ng Pilipinas (BSP). Tonik offers loans, deposits, and embedded finance via a mobile-first experience. The company is backed by leading global investors including Mizuho Bank, Insignia Ventures, Peak XV (formerly Sequoia India), and Point72 Ventures. https://tonikbank.com/ 

About Diligent Capital Partners

Diligent Capital Partners is a mid-market private equity firm created to mobilise both private and public capital to support the strengthening of the Ukrainian and wider Black Sea Region economy. It aims to catalyse the development of a healthy and dynamic corporate and financing ecosystem. With a combination of proven international expertise and deep local knowledge, the firm is uniquely positioned to seek out compelling investment opportunities. https://diligent.capital/

CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ — Nona Biosciences (“Nona” or the “Company”), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I^® (Idea to IND), today announced the appointment of Dr. Hongjiang Miao as Chief AI Officer. Dr. Miao will be based in Shanghai and report directly to Dr. Di Hong, Chief Executive Officer of Nona Biosciences.

In this role, Dr. Miao will lead the Nona AI team to advance the Company’s A³ (Antibody engineering × AI × Automation) strategy and further transform Nona into an AI-driven drug discovery company. He will be responsible for developing Nona’s AI strategy, spearheading the deep integration of AI technologies into core processes, consolidating data resources, algorithmic models, and experimental/business workflows, establishing an AI R&D platform, and enhancing platform stability and iterative upgrades.

Dr. Miao brings extensive experience in AI and biocomputing, with a proven track record of building high-performing teams and delivering impactful AI technologies. Previously, under his leadership, his team developed the first high-precision 3D protein structure prediction algorithm as well as the first AIGC protein design workbench in China, making significant contributions to computational biology and AI-driven therapeutic innovation.

Dr. Miao received his bachelor’s and master’s degrees in mathematics and statistics from the University of Oxford. He completed his doctorate at Imperial College London under the supervision of Professor Michael J.E. Sternberg, Fellow of the Royal Society of Biology, focusing on algorithms for predicting protein structure and function. Prior to joining Nona Biosciences, he served as AI CTO at Great Bay Bio and as the head of the XLab laboratory at Tianrang Intelligence.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, commented: “We are very pleased to welcome Dr. Hongjiang Miao as our first Chief AI Officer. Hongjiang is an exceptional leader who uniquely understands how to translate algorithmic innovation into biologics discovery. His expertise in AI and biocomputing will be highly valuable as we advance our A³ strategy and transform Nona into an AI-driven drug discovery company. I am confident that under his leadership, our AI technology will deeply integrate with our industry-leading antibody technology platforms, creating a truly synergistic loop that accelerates the delivery of innovative therapeutics.”

Dr. Hongjiang Miao, Chief AI Officer of Nona Biosciences, added: “It is a great honor to join Nona Biosciences, a leading innovative biotech company. Leveraging its world-class scientific team and leading innovation platform, Nona Biosciences has established integrated solutions from Idea to IND (I to I^®), ranging from target validation and antibody discovery through preclinical research, and has achieved significant breakthroughs with global impact. As Chief AI Officer, I will work closely with colleagues across all departments at Nona Biosciences to advance the company’s A³ strategy—comprehensively integrating cutting-edge AI technologies with the company’s unique biological platforms to build an intelligent engine for drug discovery. Together, we will decode the mysteries of life through algorithms, drive precision medicine with data, and continuously deliver more valuable products and services for patients and clients.”

About Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from I to I^® (Idea to IND), ranging from target validation and antibody discovery through preclinical research. Nona’s integrated antibody and antibody-related discovery services cover a broad range of modalities, from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice^® platforms and the experienced therapeutic antibody discovery teams.

Harbour Mice^® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. The HCAb Harbour Mice^® is the world’s first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications using fully human VH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice^®, single-B cell screening technology, NonaCarFx^TM (a direct CAR-function-based screening platform), Hu-mAtrIx^TM (an AI-driven drug discovery platform), Modalities-on-Demand^TM (a next-generation modalities solution), and end-to-end preclinical drug development services, Nona Biosciences is dedicated to driving the global invention of transformative next-generation drugs.

For more information, please visit: www.nonabio.com.

CHICAGO, Dec. 4, 2025 /PRNewswire/ — AlphaBitCore today announced the launch of its Model Context Protocol (MCP) Federated Access Platform, a unified control layer that lets enterprises connect AI to real work across their business, using the systems they already have.

Instead of adding yet another agent, workflow tool, or RPA product, AlphaBitCore gives companies one place to plug in models, agents, tools, and data, then decide what AI is allowed to do and where. The result is simple to understand – AI that can actually move tickets, update records, kick off approvals, and close loops in production, while the enterprise keeps a single, clear view of how it all runs.

“Most enterprises do not have an AI problem. They have an AI sprawl problem,” said James Rhodes, Co-Founder and CEO of AlphaBitCore. “We built AlphaBitCore so you can manage your entire AI stack in one place and finally let AI do real work inside your business, not just sit in a chatbot.”

Banks can use AlphaBitCore to let AI prepare credit memos, gather documents, run risk checks, and send files for approval, all inside existing banking, risk, and compliance systems. Product and engineering teams can ask AI to draft PRDs, open tickets, assign work, and keep documentation in sync, using the same Jira, code, and knowledge tools they already rely on. In each case, AI is no longer a separate assistant on the side. It works inside the normal tools and workflows; under rules the company sets once and reuses everywhere.

This is where AlphaBitCore differentiates itself from traditional agents, workflow tools, and RPA. Those products focus on single processes, single teams, or single vendors. AlphaBitCore is designed to sit above them as the platform where enterprises manage the whole AI estate. It connects out to MCP servers, gateways, and APIs, then pulls them into one governed environment so leaders can see what AI is doing, where it is connected, and what value it is creating.

Safety and security are built into this platform, but not as a brake. By centralizing identity, access, and auditing, AlphaBitCore lets risk and compliance teams set policy once so that product, operations, and engineering teams can move faster without renegotiating every new use case. The promise is straightforward: one place to control your AI stack, so you can scale AI across the business with confidence.

To support early adopters, AlphaBitCore is opening a limited Early Access Program for selected global institutions. Participants will receive sandbox environments, starter toolkits for banking and developer workflows, and direct collaboration with the AlphaBitCore team to identify and launch their first high value AI powered processes.

“Enterprises are tired of impressive demos that never reach production,” said GK, Co-Founder of AlphaBitCore. “Early Access is about getting a few critical workflows live, proving value quickly, and giving teams a single platform they can grow with.”

About AlphaBitCore

AlphaBitCore is a next generation AI infrastructure company focused on helping enterprises manage and scale their AI stack. Its MCP Federated Access Platform provides a unified control layer that lets AI agents and humans operate across enterprise systems with full compliance, observability, and traceability. The company serves financial institutions, wealth managers, digital banks, insurers, and global enterprises that want to move from AI experiments to a single, governed platform for AI in production.

Website: https://www.alphabitcore.com

HONG KONG, Dec. 4, 2025 /PRNewswire/ — Following the fire at Tai Po Hong Fuk Yuen on November 26, the Web3 and FinTech sectors swiftly mobilized, showcasing their social responsibility through an innovative aid model. Preliminary estimates indicate charitable donations from the industry have surpassed HKD 130 million, with funds prioritized for emergency relocation and community recovery. This response went beyond financial contributions, featuring the direct deployment of technical expertise and personnel, thereby injecting a sustainable “Tech for Good” momentum into traditional philanthropy.

Among the participating organizations, Vantage stood out by implementing a dual-track model combining financial donation with on-site deployment of a dedicated public welfare team. Working directly in the affected community to assist with relief distribution and resettlement support, the team translated the sector’s ethos of “warmth beyond code” into tangible action, demonstrating a new paradigm for Web3-powered public welfare. This integrated approach of capital and manpower not only enhanced aid efficiency but also illustrated how technology can act as a bridge connecting compassion with practical needs.

All charitable funds are now being coordinated and allocated by the relevant bodies. The collaborative multi-party effort highlights a profound integration of technological capability and humanistic spirit. As more organizations explore such innovative “online resources + offline action” pathways, disaster response mechanisms are poised to evolve toward greater efficiency and resilience.

Veeva AI delivers industry-specific AI for the next chapter in life sciences

SINGAPORE, Dec. 4, 2025 /PRNewswire/ — In a major milestone for Veeva AI, industry-specific AI for life sciences, Veeva Systems (NYSE: VEEV) today announced the availability of Veeva AI Agents for Vault CRM and PromoMats. Veeva AI in the Veeva Vault Platform and deep, specialized AI agents working in Veeva applications deliver practical AI with clear business value. Additional Veeva AI Agents for clinical, regulatory, safety, quality, medical, and commercial are planned for release throughout 2026.

“With industry-specific Veeva AI Agents working seamlessly in Veeva applications, the life sciences industry can increase productivity, customer centricity, and advance to new ways of working,” said Andy Han, senior vice president, Veeva AI. “Thanks to our customers for your collaboration as we rapidly develop practical AI that can have a significant impact on the industry.”

Veeva AI Now Available for Vault CRM

• Free Text Agent detects and flags potential issues in call notes to ensure accuracy and compliance. With more in-depth call reporting, companies gain the advantage of richer, higher quality customer insights.
• Voice Agent enables voice input for Vault CRM so it’s faster and easier for field teams to capture information and follow-up actions.
• Pre-call Agent provides insights and suggested actions from relevant data, content, activity, and trends that help field reps prepare for calls.

Veeva AI Now Available for PromoMats

• Quick Check Agent scans content using editorial, brand, market, channel, and compliance guidelines to address issues before medical, legal, regulatory (MLR) review.
• Content Agent provides context-aware insights into document text and images, answers questions, summarizes content, analyzes visuals, and draws from Quick Check Agent to assist with document review.

Veeva AI Agents work seamlessly within Veeva applications and have direct, secure access to data, documents, and workflows and operate within established user access controls, permissions, and audit trails. Customers can also configure and extend Veeva-delivered AI Agents and build their own custom agents with Veeva AI.

Veeva Business Consulting provides support for the business process design and change management necessary as companies define new business and process flows among users and agents.

For the latest Veeva AI information, customers can visit the Veeva AI Community on Veeva Connect and join tomorrow’s Q&A to learn more about Veeva AI in Vault CRM.

What the Industry is Saying About Veeva AI

“By embedding AI into every step of the customer journey — from how practitioners receive valuable information about our portfolio to how they engage with our field force — Veeva AI is ideally positioned to support us in our mission to deliver life-changing medicines to patients worldwide.”

– Greg Meyers, Executive Vice President, Chief Digital and Technology Officer
Bristol Myers Squibb

“What we’ve learned as an early access user is that the Veeva AI Quick Check Agent moves Moderna closer to a process where parts of MLR could become nearly touch-free. That’s the vision — and now we can genuinely see how we might get there.”

– Jason Benagh, Global Marketing Operations Director
Moderna

“Vault CRM and Veeva AI Agents like Pre-call Agent and Voice Agent will drive efficiencies and allow the field to focus on the value parts of their jobs. It’s good for the business, good for HCPs, and great for patients.”

– Frank Armenante, Director, Field Systems and Projects
Novo Nordisk

“Veeva is a critical system on our transformation roadmap, and it always has been. Being able to share the innovation with the leadership team and to introduce Veeva AI embedded into our Veeva applications is important to us as we expand our partnership.”

– Debbie Young, Multichannel Strategy and Customer Insights Director
Otsuka Europe

“We’re excited to use the Veeva AI Free Text Agent as part of our strategy toward building AI capabilities into our business. Veeva AI enables us to gain deeper customer insights for more effective engagement in the rare disease space.”

– Kea Lingo, Chief Information Officer
Crinetics

“Accenture was an early Veeva AI Partner because we believe that Veeva’s unique industry-specific approach to AI will meaningfully increase productivity in life sciences. With our deep expertise in life sciences and proven ability to scale AI, we look forward to working together to ensure customers gain practical value from Veeva AI.”

– Craig Robertson, Senior Managing Director, Life Sciences Americas
Accenture

“We expect Veeva AI Agents like Free Text Agent and Voice Agent will drive efficiency gains and insight capture that can have a transformative impact on how commercial teams operate into the future. EY is excited to support organizations on this journey toward next generation customer engagement.”

– Silvano Perrotta, Partner, Life Sciences Digital Transformation
Ernst & Young AG

About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.